Page 172 - 16Neonatal Jaundice_compressed
P. 172

Treatment





                          Research recommendations

                          What is the effectiveness, cost-effectiveness and safety of Clofibrate alongside phototherapy
                          versus phototherapy alone for non-haemolytic significant hyperbilirubinaemia?
                          Why this is important.
                          Existing research has  demonstrated that  Clofibrate in combination  with  phototherapy  can
                          shorten  time  spent undergoing phototherapy.  This can help minimise the disruption to
                          breastfeeding and mother-baby bonding. However no studies have been carried out in a UK
                          population.  New  placebo-controlled  double-blind  randomised  controlled  trials  in  a  UK
                          population are  needed. Population:  Term and preterm  babies with significant
                          hyperbilirubinaemia  in  the  first  28 days  of  life.  Interventions:  Clofibrate  (a  single  100mg/kg
                          dose) combined with phototherapy versus phototherapy with a placebo.  Outcome:
                          Effectiveness in terms of mean decrease in bilirubin levels and mean duration of phototherapy.
                          Extra outcomes should include adverse effects, parental bonding and parental anxiety, staff and
                          parental satisfaction with treatment and cost effectiveness. Time stamp: Sept 2009
                          What is the  clinical  and cost-effectiveness of IVIG  when used to prevent exchange
                          transfusion in newborns with haemolytic disease and rising bilirubin?

                          Why this is important.
                          Existing research has demonstrated that IVIG is effective in  preventing  the need for an
                          exchange transfusion in  babies  with  Rhesus haemolysis. New placebo-controlled double-
                          blind randomised controlled trials are needed to examine if IVIG is effective in sub-groups of
                          babies  with ABO  haemolysis, ie preterm  babies, babies  with bilirubin rising  greater than
                          10 micromol/litre per hour or babies with co-morbid illnesses such as infections. Population:
                          Term and preterm  babies  with significant hyperbilirubinaemia in the first 28 days of life.
                          Interventions: IVIG (500mg/kg over 4 hours) alongside phototherapy  versus phototherapy
                          alone. Outcome: Number of exchange transfusions needed. Extra outcomes should include
                          adverse effects, mean duration of phototherapy, parental anxiety, staff and  parental
                          satisfaction with treatment and cost effectiveness. Time stamp: Sept 2009











































                                                                                                        141
   167   168   169   170   171   172   173   174   175   176   177